PIK3CA and neoplasm: Additionally, the BRAF inhibitor vemurafenib is only effective in patients with V600 mutation-positive melanoma [12], [13], and the phosphoinositide-3-kinase (PI3K) inhibitor GDC-0941 is most effective in preclinical tumor models with PIK3CA mutations [14].